Document Detail

Pregnancy outcome after gestational exposure to mebendazole: a prospective controlled cohort study.
MedLine Citation:
PMID:  12548230     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Mebendazole is an anthelmintic that is commonly needed in women of reproductive age. Its use in pregnancy is a reason for concern for women and their health care providers. The purpose of this study was to examine the fetal safety of mebendazole. STUDY DESIGN: The Israeli Teratogen Information Service prospectively collected and followed 192 pregnancies exposed to mebendazole in pregnancy, 71.5% of whom had first-trimester exposure. Pregnancy outcome was compared with that of a matched control group, who were counseled for nonteratogenic exposure. RESULTS: There was no increase in the rate of major malformations between the groups (5/150 pregnancies [3.3%; mebendazole] vs 3/175 pregnancies [1.7%; nonteratogenic control subjects]; P =.478). There was a higher rate of elective terminations of pregnancy in the exposed group compared with the control group (22/192 pregnancies [11.5%; mebendazole] vs 3/192 pregnancies [1.6% [nonteratogenic control subjects]; P =.000). CONCLUSION: This study suggests that mebendazole does not represent a major teratogenic risk in humans when it is used in the doses that are used commonly for pinworm (Enterobius vermicularis) infestation.
Orna Diav-Citrin; Svetlana Shechtman; Judy Arnon; Israela Lubart; Asher Ornoy
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  188     ISSN:  0002-9378     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  2003 Jan 
Date Detail:
Created Date:  2003-01-27     Completed Date:  2003-02-20     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  282-5     Citation Subset:  AIM; IM    
Israeli Teratogen Information Service, Israel Ministry of Health, Jerusalem, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abnormalities, Drug-Induced / epidemiology*
Abortion, Induced / statistics & numerical data
Antinematodal Agents / adverse effects*
Birth Weight
Cohort Studies
Enterobiasis / drug therapy
Gestational Age
Maternal-Fetal Exchange
Mebendazole / administration & dosage,  adverse effects*
Pregnancy Outcome*
Prospective Studies
Risk Factors
Reg. No./Substance:
0/Antinematodal Agents; 31431-39-7/Mebendazole
Comment In:
Am J Obstet Gynecol. 2003 Jan;188(1):5-6   [PMID:  12548188 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Placenta previa in singleton and twin births in the United States, 1989 through 1998: a comparison o...
Next Document:  Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials.